Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 2 of these applications claim priority to application 61/384,209, filed Sep 17, 2010. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 8,795,658 | Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH In force · High confidence | Baxalta GmbH and Baxalta Incorporated | In force | High confidence | ||
| US 9,855,331 | Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH In force · High confidence | Baxalta GmbH and Baxalta Incorporated | In force | High confidence | ||
| Application 15/859,108 | Stabilization of Immunoglobulins Through Aqueous Formulation with Histidine at Weak Acidic to Neutral PH Abandoned Abandoned Apr 23, 2020 | Baxalta GmbH and Baxalta Incorporated | Abandoned | Abandoned Apr 23, 2020 |
3 of 3 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
2 of these are in force and held by Baxalta Incorporated.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.